148 related articles for article (PubMed ID: 19306058)
1. Aquaporin 1 (AQP1) expression is a novel characteristic feature of a particularly aggressive subgroup of basal-like breast carcinomas.
Otterbach F; Callies R; Adamzik M; Kimmig R; Siffert W; Schmid KW; Bankfalvi A
Breast Cancer Res Treat; 2010 Feb; 120(1):67-76. PubMed ID: 19306058
[TBL] [Abstract][Full Text] [Related]
2. [Aquaporin 1 expression in invasive breast carcinomas].
Otterbach F; Callies R; Kimmig R; Schmid KW; Bánkfalvi A
Pathologe; 2008 Nov; 29 Suppl 2():357-62. PubMed ID: 18841368
[TBL] [Abstract][Full Text] [Related]
3. Expression of aquaporin 1 in primary renal tumors: a prognostic indicator for clear-cell renal cell carcinoma.
Huang Y; Murakami T; Sano F; Kondo K; Nakaigawa N; Kishida T; Kubota Y; Nagashima Y; Yao M
Eur Urol; 2009 Oct; 56(4):690-8. PubMed ID: 18930582
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneous expression of the aquaporin 1 (AQP1) water channel in tumors of the prostate, breast, ovary, colon and lung: a study using high density multiple human tumor tissue microarrays.
Mobasheri A; Airley R; Hewitt SM; Marples D
Int J Oncol; 2005 May; 26(5):1149-58. PubMed ID: 15809704
[TBL] [Abstract][Full Text] [Related]
5. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
Rakha EA; Putti TC; Abd El-Rehim DM; Paish C; Green AR; Powe DG; Lee AH; Robertson JF; Ellis IO
J Pathol; 2006 Mar; 208(4):495-506. PubMed ID: 16429394
[TBL] [Abstract][Full Text] [Related]
6. Correlation of aquaporin-1 water channel protein expression with tumor angiogenesis in human astrocytoma.
El Hindy N; Bankfalvi A; Herring A; Adamzik M; Lambertz N; Zhu Y; Siffert W; Sure U; Sandalcioglu IE
Anticancer Res; 2013 Feb; 33(2):609-13. PubMed ID: 23393355
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of osteopontin in patients with triple-negative breast cancer.
Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
[TBL] [Abstract][Full Text] [Related]
8. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
9. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
[TBL] [Abstract][Full Text] [Related]
10. Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome.
Zerkowski MP; Camp RL; Burtness BA; Rimm DL; Chung GG
Cancer Invest; 2007 Feb; 25(1):19-26. PubMed ID: 17364553
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer.
Yamamoto Y; Ibusuki M; Okumura Y; Kawasoe T; Kai K; Iyama K; Iwase H
Breast Cancer Res Treat; 2008 Aug; 110(3):465-75. PubMed ID: 17805961
[TBL] [Abstract][Full Text] [Related]
12. RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast.
Kleer CG; Griffith KA; Sabel MS; Gallagher G; van Golen KL; Wu ZF; Merajver SD
Breast Cancer Res Treat; 2005 Sep; 93(2):101-10. PubMed ID: 16187229
[TBL] [Abstract][Full Text] [Related]
13. Tie2/Tek expression in breast carcinoma: correlations of immunohistochemical assays and long-term follow-up in a series of 909 patients.
Dales JP; Garcia S; Bonnier P; Duffaud F; Meunier-Carpentier S; Andrac-Meyer L; Lavaut MN; Allasia C; Charpin C
Int J Oncol; 2003 Feb; 22(2):391-7. PubMed ID: 12527939
[TBL] [Abstract][Full Text] [Related]
14. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
15. Expression of luminal and basal cytokeratins in human breast carcinoma.
Abd El-Rehim DM; Pinder SE; Paish CE; Bell J; Blamey RW; Robertson JF; Nicholson RI; Ellis IO
J Pathol; 2004 Jun; 203(2):661-71. PubMed ID: 15141381
[TBL] [Abstract][Full Text] [Related]
16. Relationship of P-cadherin expression to basal phenotype of breast carcinoma.
Potemski P; Kusińska R; Kubiak R; Piekarski JH; Płuciennik E; Bednarek AK; Kordek R
Pol J Pathol; 2007; 58(3):183-8. PubMed ID: 18074863
[TBL] [Abstract][Full Text] [Related]
17. Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status.
Shin BK; Lee Y; Lee JB; Kim HK; Lee JB; Cho SJ; Kim A
Oncol Rep; 2008 Mar; 19(3):617-25. PubMed ID: 18288392
[TBL] [Abstract][Full Text] [Related]
18. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.
Salvucci O; Bouchard A; Baccarelli A; Deschênes J; Sauter G; Simon R; Bianchi R; Basik M
Breast Cancer Res Treat; 2006 Jun; 97(3):275-83. PubMed ID: 16344916
[TBL] [Abstract][Full Text] [Related]
19. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
[TBL] [Abstract][Full Text] [Related]
20. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
Fadare O; Wang SA; Hileeto D
Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
